Navigation Links
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
Date:2/26/2013

BRIDGEWATER, N.J., Feb. 26, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company's fourth quarter and year-end 2012 financial results will be released prior to the market open on Tuesday, March 19, 2013.  Savient's executive management will host a conference call beginning at 9:00 a.m. Eastern Time on March 19, 2013, to discuss these results and to answer questions.

To participate by telephone, please dial 866-393-1565 (Domestic) or 253-237-1151 (International). The conference ID number is 99134844.  The live and archived webcast can be accessed via the Investor Relations section of the Savient website at www.savient.com.  A telephone replay will be available from 12:00 p.m. Eastern Time on March 19, 2013, through 11:59 p.m. Eastern Time on March 25, 2013, by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering conference ID number 99134844.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. In the U.S., Savient also supplies Oxandrin® (oxandrolone tablets, USP) CIII and co-promotes Kineret® (anakinra) with Swedish Orphan Biovitrum AB (Sobi). For more information, please visit the Company's website at www.savient.com.

SVNT-ICONTACT: Savient Pharmaceuticals, Inc. Burns McClellanJohn P. Hamill

Caitlyn MurphySenior Vice President and Chief Financial Officer

cmurphy@burnsmc.cominformation@savient.com

(212) 213-0006(732) 418-9300
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
3. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
4. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
5. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
6. Savient Pharmaceuticals Adopts Stockholder Rights Plan
7. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
9. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
10. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
11. Savient Announces the Election of Robert G. Savage to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... , February 18, 2017 Marapharm ... to purchase a Medical Delivery Service with the specific ... transactions between qualified patients and caregivers. The delivery service ... located in the Coachella Valley, California ... Los Angeles area to the West, population ...
(Date:2/18/2017)... Feb. 17, 2017  Pharmaceutical companies have long used advisory ... in development or already on the market.   ... industry to alter how it manages advisory board meetings. To ... Practices, LLC conducted a new study focused on key aspects ... ...
(Date:2/17/2017)... NEW HAVEN, Conn. , Feb. 17, 2017 /PRNewswire/ ... new class of drugs based on protein degradation, today ... oral androgen receptor (AR) PROTAC during a poster session ... Cancers Symposium (ASCO GU) in Orlando, FL. ... today continue to validate our platform and the potential ...
Breaking Medicine Technology:
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Florida Hospital Pepin Heart Institute ... thrombolysis machine, a state-of-the-art device that breaks up life-threatening blood clots by combining ... Foundation. , “We greatly appreciate this gift from Constellation Brands. We are also ...
(Date:2/19/2017)... RI (PRWEB) , ... February 19, 2017 , ... ... is proven to result in better care, and MEDfx and the Delaware Health ... state of Delaware. , As the nation’s first state-wide health information exchange, DHIN ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken ... Stairlift and other Butler products. Ken was impressed with the safety and reliability ... endorse the product on his show. This endorsement by Ken Matthews can be ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
Breaking Medicine News(10 mins):